- Report
- October 2024
- 195 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- April 2025
- 50 Pages
Global
From €2540EUR$2,650USD£2,123GBP
- Report
- May 2024
- 130 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- August 2022
- 120 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- January 2022
- 196 Pages
Global
From €7190EUR$7,500USD£6,008GBP
- Report
- October 2023
- 189 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- April 2025
- 50 Pages
Global
From €2540EUR$2,650USD£2,123GBP
Deferoxamine is a hematological drug used to treat iron overload in patients with thalassemia, sickle cell anemia, and other conditions. It is an iron chelator, meaning it binds to iron in the body and helps remove it from the bloodstream. Deferoxamine is administered intravenously or subcutaneously, and is available in both generic and brand-name forms. Common side effects include nausea, vomiting, and headache.
Deferoxamine is a widely used drug in the hematological market, and is often prescribed in combination with other drugs to treat iron overload. It is also used to treat acute iron poisoning, and is sometimes used off-label to treat other conditions such as lead poisoning.
Companies in the deferoxamine market include Novartis, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more